| Kaposi's sarcoma after long-acting steroids: time until remission and drug washout. | |
| | |
MedLine Citation:
|
PMID: 20110636 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Long-acting steroids (LAS) are widely used to treat various inflammatory diseases and allergies. They have many adverse effects including the inhibition of the hypothalamopituitary axis that can last several months. LAS are also strong immunosuppressors and can result in severe opportunistic infections and immunodeficiency-related malignancies. However, the time needed for immune recovery after withdrawal of LAS is unknown. Here we report a case of Kaposi's sarcoma (KS) and severe immunosuppression after a chronic triamcinolone acetonide (TA) treatment. Six months after withdrawal, traces of TA were still detected in the serum by HPLC mass spectrometry. At 8 months, the drug became undetectable, and clinical and biological signs of immune recovery - beginning of KS regression, normalization of IgG levels and CD4 T lymphocyte counts - became noticeable. We then provide a review of the literature on the time until remission of KS after immunosuppression reduction. We also reviewed the cases of KS induced by TA, and the metabolic side effects of TA when compared to standard glucocorticoids. |
| | |
Authors:
|
D Nassar; N E C Schartz; C Bouch?; A L?vy; D Kerob; F Agbalika; M Lafaurie; C Lebb? |
Related Documents
:
|
15551936 - A cumulative review of the range and incidence of significant adverse events associated... 8050146 - Stelazine-induced pigmentation. 16150036 - Inducing expertise effects in clinical case recall. 21061766 - Treatment of co2 laser induced hypopigmentation with ablative fractionated laser resurf... 7221626 - Fatal lung abscesses: review of 11 years' experience. 8300316 - Mastoiditis caused by atypical mycobacteria. |
Publication Detail:
|
Type: Case Reports; Journal Article; Review Date: 2010-01-29 |
Journal Detail:
|
Title: Dermatology (Basel, Switzerland) Volume: 220 ISSN: 1421-9832 ISO Abbreviation: Dermatology (Basel) Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-03-05 Completed Date: 2010-06-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203244 Medline TA: Dermatology Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 159-63 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, H?pital Saint-Louis, AP-HP, Paris, France. dany.nassar@inserm.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
administration & dosage,
adverse effects*,
blood Bleomycin / therapeutic use Blood Glucose / drug effects CD4 Lymphocyte Count Humans Immunoglobulin G / blood Immunosuppression / adverse effects* Insulin / therapeutic use Interferon-alpha / therapeutic use Male Middle Aged Opportunistic Infections / immunology*, pathology Paclitaxel / therapeutic use Sarcoma, Kaposi / immunology*, pathology Skin Ulcer / chemically induced, immunology Triamcinolone Acetonide / administration & dosage, adverse effects*, blood |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Blood Glucose; 0/Immunoglobulin G; 0/Interferon-alpha; 11056-06-7/Bleomycin; 11061-68-0/Insulin; 33069-62-4/Paclitaxel; 76-25-5/Triamcinolone Acetonide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Refractory Acne and 21-Hydroxylase Deficiency in a Selected Group of Female Patients.
Next Document: Control of Widespread Hypertrophic Lupus Erythematosus with T-Cell-Directed Biologic Efalizumab.